Results 151 to 160 of about 5,890 (202)

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate. [PDF]

Br J Dermatol, 2020
Senchyna A, Simon S, Cissé H, Ginouves M, Prevot G, Alcoba G, Demar M, Couppie P, Blaizot R.   +8 more
europepmc   +1 more source

Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis. [PDF]

Int J Parasitol Drugs Drug Resist
Peixoto JF, Gonçalves-Oliveira LF, Souza-Silva F, de Castro Côrtes LM, Finkelstein LC, Dias-Lopes G, Patricio BFC, Lima CGS, Rocha HVA, da Silva FC, Ferreira VF, Pereira BAS, Alves CR.   +12 more
europepmc   +1 more source

[Meglumine antimoniate].

Revista da Sociedade Brasileira de Medicina Tropical, 2001
openaire   +1 more source

Hypersensitivity eosinophilic myocarditis possibly triggered by meglumine antimoniate

Travel Medicine and Infectious Disease
Sergio A. Bolivar-Lozano, Leidy J. Medina-Lozano, Merardo Andrés Vega Báez, Diego A. Vargas-Hernández, Oscar Galves, Ana Catalina Herrera, Álvaro A. Faccini-Martínez   +6 more
openaire   +3 more sources

Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis. [PDF]

Int J Parasitol Drugs Drug Resist, 2019
Goyonlo VM, Vahabi-Amlashi S, Taghavi F.
europepmc   +1 more source

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis. [PDF]

PLoS Negl Trop Dis, 2019
Brito NC, Machado de Assis TS, Rabello A, Cota G.   +3 more
europepmc   +1 more source

Pharmacovigilance in the treatment of cutaneous leishmaniasis: adverse event profile at a reference center. [PDF]

Rev Soc Bras Med Trop
Rezende ALS, Carvalho JP, Noronha BP, Silva SN.   +3 more
europepmc   +1 more source

Direct quantitative PCR detects genetic biomarkers of antileishmanial drug resistance in clinical samples from dogs with leishmaniosis. [PDF]

BMC Vet Res
Carrasco-Martin M, Viñeta C, Martí-Carreras J, Roura X, Ferrer L, Busquets P, Vila A, Francino O.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Physico-chemical characterization of meglumine antimoniate

BioMetals, 1999
The leishmanicidal drug, meglumine antimoniate (MA), has been synthesized by the reaction of antimony oxyhydrated and N-methyl glucamine. Infrared and solid state NMR 13C analysis of MA and the ligand strongly suggests that antimony binds to N-methyl glucamine through the oxygen of C-3 carbon. Potentiometric titration indicated that, between pH 4.5 and
Frédéric Frézard, Cynthia Demicheli
exaly   +3 more sources

Embryotoxicity of meglumine antimoniate in the rat

Reproductive Toxicology, 2001
Meglumine antimoniate (MA) is a pentavalent antimonial (Sb(V)) drug used to treat leishmaniasis. Despite the fact that Sb(V) organic compounds have been used in clinical practice for more than 50 years, information on their safety during pregnancy is still scanty. This study was undertaken to evaluate the embryo/fetotoxicity of MA in the rat.
Francisco José Roma Paumgartten, Ibrahim Chahoud   +1 more
exaly   +3 more sources